Hematology and Medical Oncology is an open access journal with comprehensive peer review policy and a rapid publication process. Hematology journal is a novel journal that will focus on clinical
as well as basic science research reports in hematology and oncology including all major types of malignancies, blood disorders, and experimental therapies.
This journal provides an integrated view of modern oncology across all disciplines and welcomes all cancer type studies and has a particular focus on and not limited to: metastasis, epidemiology, cancer
research, biomarkers, prevention, pathology, radiology, cancer treatment, clinical trials, multimodality treatment and molecular biology, microenvironment, immunology and immunotherapy, targeted
and next-generation therapeutics, chemotherapy and radiotherapy, mechanisms of resistance, clinical trials, genomics, epigenomics and precision medicine, epidemiology.
Hematology journal also emphasize the growing importance of hematopoietic stem cell therapy for treatment of various benign and malignant hematologic disorders and certain solid tumors and also accept
papers on clinical research with clinical trials, including investigator-initiated, NCI-sponsored and pharmaceutical industry sponsored phase I-III trials. Hematology journal includes translational
studies applying basic science to clinical issues are particularly welcomed.
Hematology journal will feature original research, review papers, clinical studies, editorials, expert opinion and perspective papers, commentaries, case reports, brief reports and book reviews etc.,
Hematology journal welcomes direct submissions from authors: Attach your word file with e- mail and send it to firstname.lastname@example.org alternatively
Please, follow the Instructions for Authors. In the cover letter add the name and e-mail address of 5 proposed reviewers (we can choose
them or not).
Copyright is retained by the authors and articles can be freely used and distributed by others. Articles are distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published by Hematology
and Medical Oncology, is properly cited
*2020 Impact Factor is the ratio of the number of citations achieved in the year 2020 based on Google Search and Google Scholar Citations to the total number of articles published in the last two years i.e. in 2018 and 2019. Impact factor measures the quality of the Journal. If ‘X’ is the total number of articles published in 2018 and 2019, and ‘Y’ is the number of times these articles were cited in indexed journals during 2020 then, impact factor = Y/X.